AH
BPMC

Andreas Halvorsen’s Blueprint Medicines BPMC Stock Holding History

Andreas Halvorsen’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-213,050
Closed -$20.7M – 95
2021
Q1 		$20.7M Sell
213,050
-59,631
-22% -$5.95M 0.06% 85
2020
Q4 		$30.6M Sell
272,681
-1,158,086
-81% -$122M 0.08% 86
2020
Q3 		$133M Sell
1,430,767
-198,949
-12% -$15.3M 0.48% 54
2020
Q2 		$127M Buy
1,629,716
+29,249
+2% +$1.98M 0.55% 48
2020
Q1 		$93.6M Buy
1,600,467
+293,926
+22% +$18.9M 0.49% 46
2019
Q4 		$105M Buy
1,306,541
+504,902
+63% +$37.8M 0.49% 40
2019
Q3 		$58.9M Buy
801,639
+250,599
+45% +$21.7M 0.31% 45
2019
Q2 		$52M Sell
551,040
-107,621
-16% -$8.88M 0.23% 51
2019
Q1 		$52.7M Sell
658,661
-541,661
-45% -$40M 0.3% 50
2018
Q4 		$64.7M Buy
1,200,322
+1,089,222
+980% +$66.2M 0.37% 43
2018
Q3 		$8.67M Buy
+111,100
New +$7.72M 0.05% 61

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Andreas Halvorsen's BPMC Position: Q2 2021 in Review

Andreas Halvorsen sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 213,050 shares — an estimated $20.7M sold.

Andreas Halvorsen first reported a position in BPMC in Q3 2018 and held it in 11 quarters. The position peaked at $133M in Q3 2020. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Andreas Halvorsen reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Andreas Halvorsen sold 213,050 Blueprint Medicines shares in Q2 2021, an estimated $20.7M.
  • Andreas Halvorsen first reported a position in Blueprint Medicines in Q3 2018 and held it in 11 quarters.
  • Andreas Halvorsen's Blueprint Medicines position peaked at $133M in Q3 2020.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Viking Global Investors's 13F filing for Q2 2021, filed 16 Aug 2021.